Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$453.54 +1.4%	$382.18	$205.87 ▼ $469.81	$59.45B	0.32	960,051 shs	714,264 shs
BIIB Biogen	$139.94 -1.2%	$132.10	$110.04 ▼ $205.19	$20.52B	0.11	1.56 million shs	1.53 million shs
REGN Regeneron Pharmaceuticals	$567.22 +0.6%	$560.61	$476.49 ▼ $1,175.16	$60.12B	0.35	1.10 million shs	996,756 shs
UTHR United Therapeutics	$380.47 -2.8%	$303.44	$266.98 ▼ $436.95	$17.16B	0.62	559,518 shs	1.40 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	+0.10%	-1.49%	+6.65%	+45.27%	+76.31%
BIIB Biogen	+1.43%	+3.86%	+7.13%	+8.64%	-30.86%
REGN Regeneron Pharmaceuticals	-2.44%	-3.95%	-1.35%	+16.71%	-51.76%
UTHR United Therapeutics	-3.30%	+28.20%	+33.76%	+22.44%	+11.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$453.54 +1.4%	$382.18	$205.87 ▼ $469.81	$59.45B	0.32	960,051 shs	714,264 shs
BIIB Biogen	$139.94 -1.2%	$132.10	$110.04 ▼ $205.19	$20.52B	0.11	1.56 million shs	1.53 million shs
REGN Regeneron Pharmaceuticals	$567.22 +0.6%	$560.61	$476.49 ▼ $1,175.16	$60.12B	0.35	1.10 million shs	996,756 shs
UTHR United Therapeutics	$380.47 -2.8%	$303.44	$266.98 ▼ $436.95	$17.16B	0.62	559,518 shs	1.40 million shs

These 7 Stocks Will Be Magnificent in 2025

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	+0.10%	-1.49%	+6.65%	+45.27%	+76.31%
BIIB Biogen	+1.43%	+3.86%	+7.13%	+8.64%	-30.86%
REGN Regeneron Pharmaceuticals	-2.44%	-3.95%	-1.35%	+16.71%	-51.76%
UTHR United Therapeutics	-3.30%	+28.20%	+33.76%	+22.44%	+11.08%

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$2.25B	26.44	N/A	N/A	$1.91 per share	237.46
BIIB Biogen	$9.68B	2.12	$24.47 per share	5.72	$120.28 per share	1.16
REGN Regeneron Pharmaceuticals	$14.20B	4.23	$44.63 per share	12.71	$282.48 per share	2.01
UTHR United Therapeutics	$2.88B	5.96	$35.46 per share	10.73	$159.04 per share	2.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	-$278.16M	-$2.47	N/A	509.60	N/A	-12.96%	-273.52%	-7.39%	10/30/2025 (Estimated)
BIIB Biogen	$1.63B	$10.46	13.38	8.48	1.04	15.31%	13.85%	8.32%	10/29/2025 (Estimated)
REGN Regeneron Pharmaceuticals	$4.41B	$39.68	14.29	14.92	1.93	31.37%	15.06%	11.77%	10/30/2025 (Estimated)
UTHR United Therapeutics	$1.20B	$25.62	14.85	13.84	4.62	40.36%	18.73%	16.49%	10/29/2025 (Estimated)

Latest BIIB, REGN, ALNY, and UTHR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/1/2025	Q2 2025	REGN Regeneron Pharmaceuticals	$8.43	$12.89	+$4.46	$12.81	$3.30 billion	$3.68 billion
7/31/2025	Q2 2025	ALNY Alnylam Pharmaceuticals	-$0.54	$0.32	+$0.86	-$0.51	$633.54 million	$773.69 million
7/31/2025	Q2 2025	BIIB Biogen	$3.93	$5.47	+$1.54	$4.33	$2.32 billion	$2.65 billion
7/30/2025	Q2 2025	UTHR United Therapeutics	$6.80	$6.41	-$0.39	$6.41	$802.13 million	$798.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$3.52	0.62%	N/A	8.87%	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest BIIB, REGN, ALNY, and UTHR Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/1/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.6%	8/18/2025	8/18/2025	9/3/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	4.10	2.80	2.75
BIIB Biogen	0.36	2.50	1.79
REGN Regeneron Pharmaceuticals	0.09	4.60	3.72
UTHR United Therapeutics	N/A	7.26	6.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BIIB Biogen	87.93%
REGN Regeneron Pharmaceuticals	83.31%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	1.20%
BIIB Biogen	0.18%
REGN Regeneron Pharmaceuticals	7.02%
UTHR United Therapeutics	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,230	131.08 million	129.51 million	Optionable
BIIB Biogen	7,605	146.62 million	146.35 million	Optionable
REGN Regeneron Pharmaceuticals	15,106	105.99 million	98.55 million	Optionable
UTHR United Therapeutics	1,305	45.11 million	40.46 million	Optionable

BIIB, REGN, ALNY, and UTHR Headlines

Recent News About These Companies

Insider Selling: United Therapeutics (NASDAQ:UTHR) Director Sells 3,000 Shares of Stock

1 hour ago | marketbeat.com

United Therapeutics: Nebulized Tyvaso Label Expansion Possible For IPF After Study Win

3 hours ago | seekingalpha.com

United Therapeutics (NASDAQ:UTHR) Given New $564.00 Price Target at Jefferies Financial Group

5 hours ago | marketbeat.com

Biotech Stocks To Consider - September 2nd

5 hours ago | marketbeat.com

United Therapeutics (NASDAQ:UTHR) Given New $463.00 Price Target at Bank of America

5 hours ago | marketbeat.com

United Therapeutics (NASDAQ:UTHR) Reaches New 52-Week High - Here's Why

September 4 at 10:51 AM | marketbeat.com

Birchview Capital LP Sells 2,500 Shares of United Therapeutics Corporation $UTHR

September 4 at 7:16 AM | marketbeat.com

United Therapeutics Corporation $UTHR Shares Purchased by MPM Bioimpact LLC

September 4 at 7:02 AM | marketbeat.com

Palo Alto Investors LP Sells 50,486 Shares of United Therapeutics Corporation $UTHR

September 4 at 6:40 AM | marketbeat.com

United Therapeutics Corporation $UTHR Shares Bought by Panagora Asset Management Inc.

September 4 at 5:23 AM | marketbeat.com

Bank of America Forecasts Strong Price Appreciation for United Therapeutics (NASDAQ:UTHR) Stock

September 4 at 2:27 AM | americanbankingnews.com

Buy Rating for United Therapeutics: Promising TETON-2 Trial Results Highlight Tyvaso’s Potential in IPF Treatment

September 4 at 2:50 AM | tipranks.com

United Therapeutics Earns Membership In 95-Plus Composite Rating Club

September 3 at 3:18 PM | msn.com

UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals

September 3 at 2:51 PM | zacks.com

United Therapeutics Stock (UTHR) Opinions on Positive Tyvaso Trial Results

September 3 at 10:30 AM | quiverquant.comQ

United Therapeutics rises 42.1%

September 3 at 10:17 AM | msn.com

United Thera Phase III win for Tyvaso

September 3 at 10:17 AM | thepharmaletter.comT

United Therapeutics price target raised to $564 from $432 at Jefferies

September 3 at 10:17 AM | msn.com

Morning Movers: United Therapeutics surges after TETON-2 met primary endpoint

September 3 at 10:17 AM | finance.yahoo.com

United Therapeutics: Is UTHR Stock Still A Buy At $400?

September 3 at 10:17 AM | forbes.com

United Therapeutics’ Tyvaso Shines in Phase III Trial, Poised for Growth in IPF Market

September 3 at 7:31 AM | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIIB, REGN, ALNY, and UTHR Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$453.54 +6.11 (+1.37%)

Closing price 04:00 PM Eastern

Extended Trading

$453.60 +0.06 (+0.01%)

As of 04:47 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen NASDAQ:BIIB

$139.94 -1.68 (-1.19%)

Closing price 04:00 PM Eastern

Extended Trading

$139.74 -0.20 (-0.14%)

As of 06:32 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Regeneron Pharmaceuticals NASDAQ:REGN

$567.22 +3.42 (+0.61%)

Closing price 04:00 PM Eastern

Extended Trading

$568.26 +1.03 (+0.18%)

As of 06:53 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

United Therapeutics NASDAQ:UTHR

$380.47 -10.98 (-2.80%)

Closing price 04:00 PM Eastern

Extended Trading

$381.82 +1.35 (+0.36%)

As of 06:38 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BIIB, REGN, ALNY, and UTHR Earnings

Compare Dividends

Latest BIIB, REGN, ALNY, and UTHR Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BIIB, REGN, ALNY, and UTHR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIIB, REGN, ALNY, and UTHR Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Regeneron Pharmaceuticals NASDAQ:REGN

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BIIB, REGN, ALNY, and UTHR Earnings

Compare Dividends

Latest BIIB, REGN, ALNY, and UTHR Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BIIB, REGN, ALNY, and UTHR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIIB, REGN, ALNY, and UTHR Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Regeneron Pharmaceuticals NASDAQ:REGN

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools